Be the first person to write a business review for ARCA biopharma, Inc.

Archemix Corp., a biotechnology company, engages in discovering, developing, and commercializing aptamer therapeutics for the prevention and treatment of chronic and acute diseases in Massachusetts. The company’s aptamer product candidates include ARC1779 for thrombotic microangiopathyies and carotid endarterectomy surgical procedure. It also offers product candidates for cardiovascular, hematology, and oncology diseases. Archemix Corp. was incorporated in 2000 and is based in Cambridge, Massachusetts.

Argenta Discovery hopes to find some help for those suffering from respiratory diseases. The pharmaceutical research and development company's quest focuses on discovering treatments for allergic asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. With seven products in various preclinical and clinical testing stages, Argenta has ongoing strategic alliances with AstraZeneca, Domantis, and Dr. Reddy's to help develop certain compounds once they clear phase II trials. Argenta also performs fee-for-service research for third-party clients which have included Genentech, Zafgen, Antisoma, and Novartis. Argenta was spun off from Aventis (now Sanofi-Aventis) in 2000.

ARIAD Pharmaceuticals, Inc. company was founded in 1991 and is based in Cambridge, Massachusetts. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company engaged in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules. The Company’s lead cancer product candidate, deforolimus, is an internally discovered, potent inhibitor of the protein mTOR, a master switch in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism and angiogenesis. Its second product candidate, AP24534, is a multi-targeted kinase inhibitor that has potential applications in cancer and is wholly owned by the Company. The company also focused drug discovery program centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. It also developed a portfolio of cell-signaling regulation technologies, its ARGENT technology, to control intracellular processes with small molecules.

ARIUS Research Inc. company was founded in 1999 and is based in Toronto, Canada. As of September 23, 2008, Arius Research Inc. operates as a subsidiary of Roche Holding AG. ARIUS Research, Inc., a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform, FunctionFIRST. The company’s product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company Limited.

Ark Therapeutics is loading its boat with therapies that target cancer and vascular disease. The biotech company has one product on the market in the UK and the US -- Kerraboot, a wound dressing that treats chronic leg and foot ulcers. Lead candidate Cerepro has shown promise in extending the lives of brain tumor patients. And it has two other clinical-stage candidates that may treat cancer-related muscle wasting and prevent blood vessels from blocking after vascular graft surgery. The firm develops and markets its own products in key markets, such as Europe and the US; it largely develops drugs for indications where it has a good chance of getting the regulatory privileges of Fast Track or Orphan Drug status.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.